Comparing to Novo Nordisk, our simaglutide API has lower impurity
BPP first worked with TOMs but soon found its contractor-oriented model restrictive
Sanofi Industry Developments July 2026: Novo Nordisk received CDSCO approval for Wegovy (semaglutide) as the first and only GLP-1 receptor agonist approved in India for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, expanding the drug's indication beyond weight management and type 2 diabetes
Individuals with genetic slow-metabolizer phenotypes, chronic liver disease, malnutrition, or concurrent enzyme-inhibiting medications should discuss lower thresholds with their provider before regular acetaminophen use
These investigations contribute to expanding scientific understanding of how individual growth hormone domains influence peptide biology
Intraperitoneal injection of NAC began in the eighth week of alcohol modeling, once a day, for 2 weeks
